Pharmaceuticals Global On demand · 24-48h

Global Induced Pluripotent Stem Cell Screening Platform Market Strategic Research Report

Global Induced Pluripotent Stem Cell Screening Platform Mark…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Induced Pluripotent Stem Cell Screening Platform Market
$1.8B2025
13.9%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Cellular Reprogramming & Derivation Platforms, High-Content Imaging & Phenotypic Screening Systems, Gene Editing & CRISPR-Integrated iPSC Platforms, Automated Liquid Handling & Colony Picking Systems, AI-Driven Bioinformatics & iPSC Analytics Software

By Application: Drug Discovery & Compound Toxicity Screening, Disease Modelling & Target Identification, Cell Therapy Development & Manufacturing, Developmental Biology & Organoid Research, Neurodegenerative Disease Research

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Thermo Fisher Scientific, Fujifilm (CDI), Miltenyi Biotec, Nikon BioImaging, Revvity (PerkinElmer), Sartorius AG, BD Biosciences, Molecular Devices, Bit.bio, REPROCELL Inc.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Market size 2025
$1.8B
Billion USD
Forecast CAGR
13.9%
2025-2032
Forecast 2032
$4.5B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

نظرة عامة

The global induced pluripotent stem cell (iPSC) screening platform market represents one of the most scientifically consequential segments within life sciences tools and technologies. iPSC screening platforms encompass the integrated hardware, software, reagent systems, and assay kits used to reprogram somatic cells into pluripotent states, characterize their differentiation potential, and evaluate compound libraries for drug discovery, toxicology, and cell therapy development. Valued at approximately USD 1.8 billion in 2024, the market occupies a strategic intersection between regenerative medicine, pharmaceutical R&D, and precision oncology-market-strategic-research-report" title="Global Oncology Market Strategic Research Report">oncology — positioning it as a high-priority area for both established life science instrument companies and specialist biotech firms seeking to accelerate translational pipelines.

Several forces are propelling sustained revenue expansion. First, the rapid industrialization of cell therapy development — particularly CAR-T and iPSC-derived NK cell programs — is creating institutional demand for high-throughput, reproducible screening workflows that can process thousands of clonal lines per campaign. Organizations such as the FDA and EMA have concurrently updated guidance frameworks for advanced therapy medicinal products (ATMPs), mandating rigorous identity and potency characterization that iPSC platforms are uniquely positioned to address. Second, the convergence of artificial intelligence with imaging-based phenotypic screening has materially reduced the false-positive burden in early-stage drug discovery; AI-guided morphological profiling of iPSC-derived cardiomyocytes and neurons now generates mechanistic insight that conventional biochemical assays cannot replicate. A meaningful restraint, however, is the complexity and cost of iPSC reprogramming and quality control: generating a clinical-grade, fully characterized iPSC line can require 12–18 months and expenditures exceeding USD 500,000, limiting adoption among smaller research institutions and constraining the pace at which disease-relevant cell models enter commercial screening catalogs.

This report delivers a comprehensive, data-anchored analysis of the global iPSC screening platform market across the 2025–2032 forecast period, segmented by platform type, application, and geography to a country level. It profiles ten leading companies with granular competitive assessments and examines the technological, regulatory, and investment trends shaping the next generation of iPSC-enabled discovery. Corporate strategy teams evaluating portfolio adjacencies, investment analysts tracking life science tools, M&A advisors benchmarking asset valuations, and procurement managers sourcing enterprise screening infrastructure will each find targeted, decision-relevant intelligence within this report.

Market snapshot

Global Induced Pluripotent Stem Cell Screening Platform Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 13.9%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.8B
2025
Forecast
$4.5B
2032
CAGR
13.9%
2025–2032
Regions
5
global
Key companies
Thermo Fisher ScientificFujifilm (CDI)Miltenyi BiotecNikon BioImagingRevvity (PerkinElmer)Sartorius AGBD BiosciencesMolecular Devices
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Cellular Reprogramming & Derivation PlatformsHigh-Content Imaging & Phenotypic Screening SystemsGene Editing & CRISPR-Integrated iPSC PlatformsAutomated Liquid Handling & Colony Picking SystemsAI-Driven Bioinformatics & iPSC Analytics Software
By Application
Drug Discovery & Compound Toxicity ScreeningDisease Modelling & Target IdentificationCell Therapy Development & ManufacturingDevelopmental Biology & Organoid ResearchNeurodegenerative Disease Research

Table of contents

Click a chapter to expand
01Executive Summary
  • 1.1 Market Synopsis
  • 1.2 Key Findings
  • 1.3 Strategic Recommendations
02Industry Overview & Forecast
  • 2.1 Market Definition & Scope
  • 2.2 Market Value Forecast, 2025-2032 (Value)
  • 2.3 CAGR Analysis & Confidence Intervals
  • 2.4 Historical Market Review, 2019-2024
  • 2.5 Scenario Analysis (Base, Bull, Bear Cases)
03Market Segmentation by Type
  • 3.1 Market by Type Overview
  • 3.2 Cellular Reprogramming & Derivation Platforms (Value)
  • 3.3 High-Content Imaging & Phenotypic Screening Systems (Value)
  • 3.4 Gene Editing & CRISPR-Integrated iPSC Platforms (Value)
  • 3.5 Automated Liquid Handling & Colony Picking Systems (Value)
  • 3.6 AI-Driven Bioinformatics & iPSC Analytics Software (Value)
04Market Segmentation by Application
  • 4.1 Market by Application Overview
  • 4.2 Drug Discovery & Compound Toxicity Screening (Value)
  • 4.3 Disease Modelling & Target Identification (Value)
  • 4.4 Cell Therapy Development & Manufacturing (Value)
  • 4.5 Developmental Biology & Organoid Research (Value)
  • 4.6 Neurodegenerative Disease Research (Value)
05Regional Market Forecast
  • 5.1 Regional Revenue Share & CAGR (2024 vs 2032)
  • 5.2 North America (Value)
  • 5.3 Europe (Value)
  • 5.4 Asia Pacific (Value)
  • 5.5 Middle East & Africa
  • 5.6 Latin America
06Country-Level Market Forecast
  • 6.1 Top Countries Overview
  • 6.2 United States
  • 6.3 Japan
  • 6.4 United Kingdom
  • 6.5 Germany
  • 6.6 China
  • 6.7 South Korea
07Growth Drivers & Inhibitors
  • 7.1 Expansion of iPSC-Derived Cell Therapy Clinical Pipelines (CAR-T, NK, RPE Programs)
  • 7.2 Adoption of AI-Guided Morphological Profiling in Phenotypic Drug Discovery
  • 7.3 Regulatory Mandates for ATMP Identity & Potency Characterization Under FDA and EMA Frameworks
  • 7.4 Market Restraints & Challenges
  • 7.5 Opportunities & White-Space Analysis
08Key Company Profiles
  • 8.1 Thermo Fisher Scientific — Revenue, Strategy, Key Products
  • 8.2 Fujifilm Holdings (Cellular Dynamics International) — Revenue, Strategy, Key Products
  • 8.3 Miltenyi Biotec — Revenue, Strategy, Key Products
  • 8.4 Nikon Corporation (BioImaging Solutions) — Revenue, Strategy, Key Products
  • 8.5 PerkinElmer (Revvity) — Revenue, Strategy, Key Products
  • 8.6 Sartorius AG — Revenue, Strategy, Key Products
  • 8.7 Becton, Dickinson and Company (BD Biosciences) — Revenue, Strategy, Key Products
  • 8.8 Molecular Devices (Danaher) — Revenue, Strategy, Key Products
  • 8.9 Bit.bio — Revenue, Strategy, Key Products
  • 8.10 REPROCELL Inc. — Revenue, Strategy, Key Products
09Competitive Landscape
  • 9.1 Market Concentration & Competitive Intensity
  • 9.2 Market Share Analysis (2024)
  • 9.3 Competitive Positioning Matrix
  • 9.4 Recent Developments: M&A, Partnerships & Product Launches (2023-2025)
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitute Products
  • 10.5 Competitive Rivalry Intensity
11PESTLE Analysis
  • 11.1 Political Factors
  • 11.2 Economic Factors
  • 11.3 Social & Demographic Factors
  • 11.4 Technological Factors
  • 11.5 Legal & Regulatory Factors
  • 11.6 Environmental Factors
12SWOT Analysis
  • 12.1 Market-Level Strengths
  • 12.2 Market-Level Weaknesses
  • 12.3 Strategic Opportunities
  • 12.4 External Threats
13Future Trends & Outlook
  • 13.1 Integration of Organoid-on-Chip Systems with iPSC Screening Workflows
  • 13.2 Emergence of Off-the-Shelf Allogeneic iPSC Line Repositories for Standardized Screening
  • 13.3 Multimodal Single-Cell Omics Paired with iPSC Phenotypic Platforms for Target Deconvolution
  • 13.4 Long-Term Market Outlook (2033-2035)
  • 13.5 Investment & M&A Activity Outlook

Frequently asked questions

What is the size of the induced pluripotent stem cell screening platform market?
The global iPSC screening platform market was valued at approximately USD 1.8 billion in 2024. It is forecast to reach approximately USD 5.1 billion by 2032, driven by the industrialization of cell therapy pipelines, adoption of AI-assisted phenotypic screening, and tightening ATMP regulatory requirements across the US, EU, and Asia.
What is the CAGR of the induced pluripotent stem cell screening platform market?
The market is projected to expand at a compound annual growth rate (CAGR) of approximately 13.9% over the 2025–2032 forecast period, reflecting accelerating investment in iPSC-based drug discovery infrastructure and cell therapy manufacturing quality systems globally.
What is driving growth in the induced pluripotent stem cell screening platform market?
Three primary drivers underpin market growth. First, the rapid expansion of iPSC-derived cell therapy clinical programs — including CAR-T, NK cell, and retinal pigment epithelium therapies — is creating institutional demand for high-throughput, reproducible screening workflows. Second, AI-guided morphological profiling applied to iPSC-derived cardiomyocytes and neurons is materially improving compound prioritization in phenotypic drug discovery programs. Third, updated FDA and EMA regulatory guidance for ATMPs mandates rigorous identity, genomic stability, and potency characterization, directly increasing demand for validated iPSC screening platforms.
Who are the leading companies in the induced pluripotent stem cell screening platform market?
Key players in the iPSC screening platform market include Thermo Fisher Scientific, which offers comprehensive iPSC culture and characterization reagents; Fujifilm Holdings through its Cellular Dynamics International subsidiary, a leading supplier of iPSC-derived cell types; Miltenyi Biotec, known for its CliniMACS and cell processing platforms; Molecular Devices (Danaher), offering high-content imaging systems widely deployed in iPSC phenotypic screening; and Sartorius AG, which provides integrated bioprocess and cell analytics instruments relevant to clinical-scale iPSC workflows.
Which region dominates the induced pluripotent stem cell screening platform market?
North America holds the largest revenue share of the global iPSC screening platform market, accounting for an estimated 42% of total market value in 2024. This dominance reflects the concentration of major pharmaceutical and biotech R&D operations, the presence of leading academic medical centers with established iPSC programs, substantial NIH and BARDA funding for regenerative medicine, and a mature regulatory framework for cell therapy development. Asia Pacific, led by Japan and China, represents the fastest-growing region given significant government-backed iPSC research initiatives and a growing domestic cell therapy industry.
What segments are covered in this report?
The report segments the iPSC screening platform market by platform type — covering cellular reprogramming and derivation platforms, high-content imaging and phenotypic screening systems, gene editing and CRISPR-integrated platforms, automated liquid handling and colony picking systems, and AI-driven bioinformatics software — and by application, covering drug discovery and compound toxicity screening, disease modelling and target identification, cell therapy development and manufacturing, developmental biology and organoid research, and neurodegenerative disease research. Regional and country-level segmentation is also provided.
What is the forecast period covered in this report?
This report covers a forecast period of 2025 to 2032, with 2024 as the base year. Historical market data is reviewed from 2019 to 2024 to establish trend continuity and validate the forecast model.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from ‏3,500.00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.